FRM
CLVS

Fox Run Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Fox Run Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-19,830
Closed -$134K – 356
2020
Q2 		$134K Buy
+19,830
New +$150K 0.18% 236
2019
Q1 		– Sell
-44,774
Closed -$804K – 751
2018
Q4 		$804K Buy
44,774
+18,460
+70% +$377K 0.43% 22
2018
Q3 		$773K Buy
+26,314
New +$1.02M 0.34% 42
2018
Q2 		– Sell
-15,982
Closed -$844K – 972
2018
Q1 		$844K Buy
+15,982
New +$932K 0.2% 128
2016
Q3 		– Sell
-11,200
Closed -$154K – 744
2016
Q2 		$154K Buy
+11,200
New +$164K 0.07% 474

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return